BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 21699063)

  • 1. SiRNA delivery: challenges and role of carrier systems.
    Shegokar R; Al Shaal L; Mishra PR
    Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S; Zhao B; Jiang H; Wang B; Ma B
    J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
    Gary DJ; Puri N; Won YY
    J Control Release; 2007 Aug; 121(1-2):64-73. PubMed ID: 17588702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivering silence: advancements in developing siRNA therapeutics.
    Novobrantseva TI; Akinc A; Borodovsky A; de Fougerolles A
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):217-24. PubMed ID: 18283609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo delivery of RNAi with lipid-based nanoparticles.
    Huang L; Liu Y
    Annu Rev Biomed Eng; 2011 Aug; 13():507-30. PubMed ID: 21639780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA.
    Yang XZ; Dou S; Wang YC; Long HY; Xiong MH; Mao CQ; Yao YD; Wang J
    ACS Nano; 2012 Jun; 6(6):4955-65. PubMed ID: 22646867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Types of non-viral delivery systems of small interfering RNA].
    Glebova KV; Marakhonov AV; Baranova AV; Skoblov MIu
    Mol Biol (Mosk); 2012; 46(3):387-401. PubMed ID: 22888629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A non-covalent peptide-based strategy for siRNA delivery.
    Crombez L; Charnet A; Morris MC; Aldrian-Herrada G; Heitz F; Divita G
    Biochem Soc Trans; 2007 Feb; 35(Pt 1):44-6. PubMed ID: 17233597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the development of siRNA-based therapeutics for cancer.
    Shen Y
    IDrugs; 2008 Aug; 11(8):572-8. PubMed ID: 18683092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why RNAi makes sense.
    Hough SR; Wiederholt KA; Burrier AC; Woolf TM; Taylor MF
    Nat Biotechnol; 2003 Jul; 21(7):731-2. PubMed ID: 12833082
    [No Abstract]   [Full Text] [Related]  

  • 17. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles.
    Tamura A; Nagasaki Y
    Nanomedicine (Lond); 2010 Sep; 5(7):1089-102. PubMed ID: 20874023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
    Spagnou S; Miller AD; Keller M
    Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla.
    Meade BR; Dowdy SF
    Discov Med; 2009 Dec; 8(43):253-6. PubMed ID: 20040280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.